May 2021 tender notification
PHARMAC is pleased to provide the latest tender results.
Tender results
PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 June 2021 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2020/21 Tender – Principal Supply Status applies until 30 June 2024
CORRECTION to February 2021 tender notification
PHARMAC incorrectly notified a Principal Supply Status award in the Community and Hospital in February 2021 for betamethasone dipropionate with calcipotriol as ‘tube’ when this should have been a ‘bottle’. Correction in strikethrough and bold below:
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
---|---|---|---|---|---|---|
Betamethasone dipropionate with calcipotriol |
Gel 500 mcg with calcipotriol 50 mcg per g, 60 g tube bottle |
$52.24 |
$39.35 |
Daivobet (LEO Pharma) |
1 July 2021 |
1 December 2021 |
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
---|---|---|---|---|---|---|---|
Betamethasone dipropionate with calcipotriol |
Gel 500 mcg with calcipotriol 50 mcg per g, 60 g tube bottle |
$52.24 |
$39.35 |
Daivobet (LEO Pharma) |
5% |
1 July 2021 |
1 December 2021 |
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
---|---|---|---|---|---|---|
Modafinil1 |
Tab 100 mg; 60 tablet blister pack |
$64.00 |
$29.13 |
Modavigil |
1 October 2021 |
1 March 2022 |
1This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender. |
See table 5 below for changes to the Pharmaceutical Schedule in relation to azacitidine.
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of subsidy change |
Principal Supply date |
Brand |
---|---|---|---|---|---|---|---|
Flucloxacillin cap
|
cap 250 mg; 250 capsule bottle |
$16.83 |
$15.79 |
Flucloxacillin-AFT |
1 December 2021 |
1 May 2022 |
Staphlex |
Flucloxacillin cap |
cap 500 mg; 500 capsule bottle |
$56.61 |
$52.99 |
Flucloxacillin-AFT |
1 December 2021 |
1 May 2022 |
Staphlex |
Melatonin2 |
Tab modified-release 2 mg; 30 tablet blister pack |
$28.22 |
$11.50 |
Vigisom |
1 November 2021 |
1 April 2022 |
Circadin |
Travoprost |
Eye drops 0.004%; 2.5 ml OP |
$19.50 |
$9.75 |
Travatan (pharmacode 2550091)(Novartis) |
1 July 2021 |
1 December 2021 |
Travatan (pharmacode 2144581) Mylan (pharmacode 2602296) Travopt (pharmacode 2523035) |
2 Brand switch fee of $4.50 is payable for this product from 1 April 2022 to 30 June 2022 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Listing date |
Principal Supply Status date |
|
---|---|---|---|---|---|---|---|---|
Azacitidine3 |
Inj 100 mg vial, 1 vial pack |
$139.00 |
$75.06 |
Azacitidine Dr Reddy’s |
5% |
1 July 2021 |
1 December 2021 |
|
Linezolid |
Inj 2 mg per ml; 300 ml bottle |
$18.50 (per 1) |
$155.00 (per 10) |
Linezolid Kabi |
5% |
1 July 2021 |
1 December 2021 |
|
Modafinil4 |
Tab 100 mg; 60 tablet blister pack |
$64.00 |
$29.13 |
Modavigil |
5% |
1 October 2021 |
1 March 2022 |
|
3 The price and subsidy of azacitidine (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2021. The subsidy of azacitidine (Baxter) inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will also be amended from $1.53 per 1 mg to $0.83 per 1 mg from 1 July 2021. 4 This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender. |
|
6. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
Brand |
---|---|---|---|---|---|---|---|---|
Flucloxacillin cap
|
cap 250 mg; 250 capsule bottle |
$16.83 |
$15.79 |
Flucloxacillin-AFT |
5% |
1 December 2021 |
1 May 2022 |
Staphlex (Mylan) |
Flucloxacillin cap |
cap 500 mg; 500 capsule bottle |
$56.61 |
$52.99 |
Flucloxacillin-AFT |
5% |
1 December 2021 |
1 May 2022 |
Staphlex (Mylan) |
Melatonin |
Tab modified-release 2 mg; 30 tablet blister pack |
$28.22 |
$11.50 |
Vigisom |
5% |
1 November 2021 |
1 April 2022 |
Circadin (Aspen Pharma) |
Milrinone |
Inj 1 mg per ml, 10 ml ampoule; 10 ampoule pack |
$99.00 |
$71.00 |
Milrinone-Baxter |
5% |
1 July 2021 |
1 December 2021 |
Primacor (Sanofi-Aventis) |
Travoprost |
Eye drops 0.004%; 2.5 ml |
$19.50 |
$9.75 |
Travatan (pharmacode 2550091) |
5% |
1 July 2021 |
1 December 2021 |
Travopt |
Tender declines - Products where no tender is to be awarded for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2020/21 Invitation to Tender, dated 2 November 2020
- the 2019/20 Invitation to Tender, dated 1 November 2019
2020/21 Invitation to Tender
Chemical name |
Line item |
---|---|
Alprostadil |
Inj 500 mcg per ml, 1 ml |
Azacitidine (widened access) |
Inj 100 mg |
Azithromycin |
Grans for oral liq 200 mg per 5 ml |
Cabergoline |
Tab 0.5 mg (2 pack) |
Cabergoline |
Tab 0.5 mg (8 pack) |
Calcium Gluconate |
Inj 10%, 10 ml |
Cisplatin |
Inj 1 mg per ml, 50 ml |
Desferrioxamine mesilate |
Inj 500 mg |
Diclofenac sodium |
Inj 25 mg per ml, 3 ml |
Diclofenac sodium |
Suppos 100 mg |
Diclofenac sodium |
Suppos 12.5 mg |
Diclofenac sodium |
Suppos 25 mg |
Diclofenac sodium |
Suppos 50 mg |
Diclofenac sodium |
Tab 50 mg dispersible |
Disopyramide phosphate |
Cap 100 mg |
Efavirenz |
Tab 200 mg |
Efavirenz |
Tab 50 mg |
Efavirenz |
Tab 600 mg |
Efavirenz |
Oral liq 30 mg per ml |
Ferrous sulphate with ascorbic acid |
tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 |
Glyceryl trinitrate |
Inj 1 mg per mL, 10 mL |
Hydrocortisone |
Oint 1% (pack size greater than 100 g) |
Hydrocortisone |
Oint 1% (pack size 100 g or less) |
Idarubicin Hydrochloride |
Inj 10 mg |
Idarubicin Hydrochloride |
Inj 5 mg |
Lidocaine [Lignocaine] Hydrochloride |
Gel 2% |
Lopinavir with Ritonavir |
Oral liq 80 mg with ritonavir 20 mg per ml |
Netupitant with Palonosetron |
Cap netupitant 300 mg with palonosetron 500 mcg |
Noradrenaline |
Inj 0.06 mg per ml, 100 ml bag |
Noradrenaline |
Inj 0.12 mg per ml, 50 ml syringe |
Noradrenaline |
Inj 0.16 mg per ml, 100 ml bag |
Noradrenaline |
Inj 0.16 mg per ml, 50 ml vial |
Noradrenaline |
Inj 1 mg per ml, 100 ml bag |
Pamidronate disodium |
Inj 3 mg per ml, 10 ml |
Pamidronate disodium |
Inj 6 mg per ml, 10 ml |
Pamidronate disodium |
Inj 9 mg per ml, 10 ml |
Pancreatic enzyme |
Cap 175 mg |
Povidone Iodine |
Antiseptic soln 10% (pack size 15 ml or less) |
Povidone Iodine |
Antiseptic soln 10% (pack size greater than 100 ml) |
Povidone Iodine |
Skin preparation, povidone iodine 10% with 30% alcohol (pack size 100 ml or less) |
Povidone Iodine |
Skin preparation, povidone iodine 10% with 30% alcohol (pack size greater than 100 ml) |
Povidone Iodine |
Skin preparation, povidone iodine 10% with 70% alcohol (pack size 100 ml or less) |
Povidone Iodine |
Skin preparation, povidone iodine 10% with 70% alcohol (pack size greater than 100 ml) |
Ziprasidone |
Cap 80 mg |
2019/20 Invitation to Tender
Insulin pen needles |
29 g x 12.7 mm |
Insulin pen needles |
31 g x 5 mm |
Insulin pen needles |
31 g x 6 mm |
Insulin pen needles |
31 g x 8 mm |
Insulin pen needles |
32 g x 4 mm |
Insulin syringes, disposable with attached needle: |
0.3 ml with 29 g x 12.7 mm needle |
Insulin syringes, disposable with attached needle: |
0.3 ml with 31 g x 8 mm needle |
Insulin syringes, disposable with attached needle: |
0.3 ml with 29 g x 6 mm needle |
Insulin syringes, disposable with attached needle: |
0.5 ml with 29 g x 12.7 mm needle |
Insulin syringes, disposable with attached needle: |
0.5 ml with 31 g x 8 mm needle |
Insulin syringes, disposable with attached needle: |
0.5 ml with 29 g x 6 mm needle |
Insulin syringes, disposable with attached needle: |
1 ml with 29 g x 12.7 mm needle |
Insulin syringes, disposable with attached needle: |
1 ml with 31 g x 8 mm needle |
Insulin syringes, disposable with attached needle: |
1 ml with 29 g x 6 mm needle |
Mupirocin |
Intra-nasal ointment 2% |
Mupirocin |
Topical ointment 2% |
Phenylephrine hydrochloride |
Inj 10 mg per ml, 1 ml vial |
Zinc |
cream (pack size 50 g or less) |
Zinc |
cream (pack size greater than 50 g) |
Zinc |
ointment (pack size 50 g or less) |
Zinc |
ointment (pack size greater than 50 g) |
Zinc |
paste (pack size 50 g or less) |
For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.